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Background and Objectives. Transferrin receptor (TfR)
expression in erythroid cells is regulated by a number of
factors, including iron status and erythropoietin (Epo)
stimulation. However, the impact of these factors on retic-
ulocyte TfR expression in vivo has never been studied. A
soluble form of TfR (sTfR) is present in serum in propor-
tion to the mass of cellular TfR. Although sTfR shedding
by reticulocytes and erythroblasts has been demonstrat-
ed in vitro, the contribution of reticulocyte TfR to serum
sTfR has never been evaluated in vivo.
Design and methods. We measured directly the total
number of reticulocyte TfR in normal rats of different age
and iron status, as well as in animals experiencing vari-
ous conditions and treatments aimed at altering ery-
thropoietic activity and iron status, including rHuEpo ther-
apy, hemolytic anemia, phlebotomies, hypertransfusions,
thiamphenicol-induced red cell aplasia or inflammation.
In addition, we examined the impact of repeated hyper-
transfusions with normal, reticulocyte-poor and reticulo-
cyte-rich blood on serum sTfR levels.
Results. The number of TfR molecules per reticulocyte
was around 50,000 in young rats but was around
100,000 in older animals. These values remained con-
stant in most conditions and in particular were not influ-
enced by iron supplementation or iron overload. Howev-
er, functional iron deficiency as well as rHuEpo therapy
resulted in increased reticulocyte TfR expression. In addi-
tion, TfR numbers in reticulocytes were elevated in the
early phase of recovery after acute hemolysis or red cell
aplasia but normalized soon after. Hypertransfusion
experiments clearly demonstrated that reticulocytes can
contribute substantially to sTfR levels in vivo.
Interpretation and conclusions. TfR numbers are regu-
lated in vivo by the same factors as in vitro, in particular
iron deficiency and erythropoietin stimulation. Circulating
reticulocytes contribute significantly to serum sTfR levels.
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The transferrin receptor (TfR) mediates uptake ofplasma transferrin iron by erythroid as well as allother cell types.1-3 The functional receptor is com-
posed of two monomers linked by two disulfide bridges
to form a molecule of 190,000 Daltons. Virtually all
cells, except mature red cells, have TfR on their surface,
but the largest numbers are found on the erythron.
Many more TfR are seen on CFU-E than on BFU-E4-6
and their number increases to about 300,000 on early
normoblasts and up to 800,000 on intermediate nor-
moblasts,7 before declining to about 100,000 on retic-
ulocytes and none on mature red cells.7,8 TfR expression
is co-ordinated by a number of factors. Intracellular
iron regulates the stability of TfR mRNA by means of an
interaction between the iron regulatory proteins (IRP)
that sense changes in the chelatable iron pool, and iron-
responsive elements (IRE) on TfR mRNA.2,9 When intra-
cellular iron is abundant, IRP do not bind to IRE, result-
ing in increased mRNA degradation. When iron is
scarce, binding of IRP to IRE stabilizes TfR mRNA. Nitric
oxide also modulates IRP activity and thus enhances
TfR expression, although this may occur indirectly
through changes in intracellular iron.1,9,10 Erythropoi-
etin (Epo) increases TfR mRNA levels and cell surface
expression in erythroid cells through either changes in
transcription rates1 or enhanced binding of IRP-1 to
IRE.11 Hypoxia by itself increases TfR expression inde-
pendently of IRP activity through a hypoxia-responsive
element in the TfR gene.12,13 However, the impact of
iron status and Epo stimulation on reticulocyte TfR
expression in vivo has never been studied.
A soluble form of the TfR (sTfR) has been identified in
animal14 and human15 serum. Soluble TfR is a truncated
monomer of tissue receptor, lacking its first 100 amino
acids, which circulates in the form of a complex of trans-
ferrin and its receptor.14-16 The most important determi-
nant of sTfR levels is marrow erythropoietic activity,
which determines variations of as much as 8 times below
and 20 times above average normal values in situations
characterized by diminished or increased erythropoiesis,
respectively.14,15 Iron status also influences sTfR levels,
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which are considerably elevated in iron deficiency ane-
mia17 and already so in functional iron deficiency, a sit-
uation defined by tissue iron deficiency despite adequate
iron stores.18 Soluble TfR has thus been established as a
quantitative marker of the mass of cellular TfR. Howev-
er, the cell population predominantly involved in TfR
shedding has not been clearly identified. In vitro, trun-
cated sTfR have been shown to be released by tumor
cells,19,20 reticulocytes20,21 and erythroblasts.22 The rela-
tive contributions of reticulocytes and erythroblasts to
sTfR levels have not been determined. These are difficult
to clarify because the two categories of cells always
change in parallel, except in situations characterized by
ineffective erythropoiesis, such as thalassemia major. The
fact that the highest sTfR levels have been found in tha-
lassemic patients, in whom reticulocyte counts are quite
low, would suggest that the relative contribution of nor-
moblasts to sTfR levels predominates.15
We, therefore, carried out a study in rats to examine
the effect of iron status and erythropoiesis on the
expression of TfR in reticulocytes and to investigate the
contribution of reticulocyte TfR to sTfR levels in vivo.
Design and Methods
Animals
Male Wistar rats were obtained from Janssen (Beerse,
Belgium) and raised at the University of Liège from the
age of 3 weeks through to the end of the experiment.
All experiments were carried out under ether anesthe-
sia. Animals were fed standard granular food without
iron supplements. Hemolytic anemia was produced by
intraperitoneal injection of 50 mg acetylphenylhy-
drazine per Kg body weight, some animals receiving a
single dose on day 0 and others 3 doses given on days
0, 4 and 8 to obtain an on-going hemolysis. Red cell
aplasia was provoked by intraperitoneal injections of
thiamphenicol in one of 2 different schedules: 50 mg
b.i.d. for 4 consecutive days or 100 mg once daily for 10
consecutive days. Inflammation was generated by
injecting 0.25 mL turpentine oil in each thigh. Iron-defi-
cient erythropoiesis was induced by bleeding animals
3-4 mL on 2 consecutive days as well as on alternate
days thereafter to maintain a hematocrit of about 25-
30%. In order to suppress erythropoiesis, rats were
transfused with 3-4 mL washed packed red cells every
other day to maintain a hematocrit of 60-70%. Three
types of donor animals were used. Normal unmanipu-
lated donors had reticulocyte counts around 7%. Other
donors were previously treated with thiamphenicol to
induce red cell aplasia and so procure blood with <2%
reticulocytes. A third group of donors received phenyl-
hydrazine twice within an interval of 4 days and blood
was collected at the time of peak reticulocytosis (>30%). 
Recombinant human erythropoietin (rHuEpo, Recor-
mon®) was kindly provided by Boehringer-Mannheim
(Brussels, Belgium). Rats were injected daily with intra-
venous rHuEpo at a dose of 10, 50 or 150 U/day for up
to 20 days. Control animals (0 U rHuEpo) received the
same volume of normal saline. Some groups of rats
treated with rHuEpo were fed standard food in powder
form supplemented with 1% (w/w) carbonyl iron (Sig-
ma Chemical Co., St. Louis, USA) 6 days per week and
normal granular food 1 day per week, for a total of 2
weeks (iron supplemented rats) or 3 months (iron over-
loaded rats) before as well as during rHuEpo treatment.
Experimental procedures
Blood samples were drawn from a tail vein 3 times per
week until the final day of the experiment when ferro-
kinetic studies were performed. Labeling with 59Fe was
accomplished by adding 1 µCi 59Fe citrate to 0.5 mL
donor plasma under continuous agitation. The plasma
was then incubated for 30 minutes at 37°C before injec-
tion into a tail vein. Blood samples were obtained from
the tail vein on the opposite side and the rate of radio-
iron disappearance from circulation (t1/2) was deter-
mined by least squares regression analysis. From the
Hct, serum iron, transferrin saturation and radioiron
clearance, the erythron transferrin uptake (ETU, µmol/L
whole blood/day) was then calculated.23,24
Three hours (6 for hypertranfused animals) after radio-
iron injection, rats were exsanguinated from the abdom-
inal aorta and perfused with 20-30 mL saline. The spleen,
liver and 2 femora were removed and weighed. Whole
blood and plasma activities, as well as activity of the liv-
er, spleen and femora were counted. Total plasma and
total red cell activities were calculated from the hema-
tocrit, assuming a blood volume of 0.07 mL/g body
weight. Erythroid marrow activity was estimated by mul-
tiplying the counts of the 2 femora by 6.5.25 The 2
extremities of the femora were cut and ground and the
supernatant was obtained after centrifugation, while the
bone marrow was flushed out of the femoral shafts. The
two marrow components were combined, counted and
the efficiency of marrow extraction was calculated. All
calculations accounted for the efficiency of marrow
extraction determined for each individual animal.
The whole spleen and extracted bone marrow,
weighed aliquots of the liver, as well as washed red cells
from 1 mL whole blood were then homogenized and
transferrin receptors solubilized at 4°C in a Polytron PT-
K homogenizer (Kinematica, Littau, Switzerland) for 1
min at 15,000 rpm and then 0.5-2 min at 24,000 rpm.
All samples were homogenized in adequate amounts of
10 mM phosphate-buffered saline, pH 7.4, containing 1
mM iodoacetic acid, 0.5 mM PMSF, 20 U/mL aprotinin
and 2% of the non-ionic detergent TERIC (Sigma Chem-
ical Co., St. Louis, USA). After homogenization, samples
were centrifuged for 35 min at 51,000 g at 4°C in a
Supraspeed RC28S Sorvall centrifuge (Sorvall Instru-
ments, Du Pont Company, Wilmington, USA). The super-
natants were collected and counted to calculate the
percentage recovery of the original sample. All calcula-
tions accounted for this percentage recovery determined
for each individual sample. Soluble TfR concentration
was then measured on fresh supernatants of each
homogenized organ.
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Laboratory analyses 
Blood samples were drawn from a tail vein. Part of the
blood was drawn on ACD formula A and part on heparin
to be centrifuged to obtain plasma that was frozen at -
20°C until processing. Hematocrits were determined by
the micromethod technique. Complete blood counts
were measured on a Technicon H1 automatic cell
counter (Tarrytown, New York, USA) with appropriate
corrections for dilution by ACD. The percentage of retic-
ulocytes was determined by cytofluorometry on a FACScan
cytofluorometer (Becton Dickinson, San José, California,
USA) after coloration with thiazole orange.26 Preliminary
experiments showed that this automated method gave
results similar to manual counting on blood smears col-
ored with brilliant cresyl blue. Soluble transferrin recep-
tor (sTfR) was measured by ELISA in plasma as well as
in organ extracts as previously described with minor
modifications.14,27 Serum iron (SeFe) and total iron bind-
ing capacity (TIBC) were measured by standard meth-
ods28 and transferrin saturation was derived from these
figures.
Calculation of the mass of TfR
The concentration of sTfR measured in the super-
natant of each organ homogenate was corrected for the
recovery of radioactivity counted in the original sample
and expressed per mL (RBC and marrow) or g  (liver and
spleen) of organ. The total mass of TfR in each organ was
then calculated based on this concentration and the
total weight (liver and spleen) or volume (plasma, RBC
and marrow) of the organ considered, taking into
account the efficiency of organ extraction for the bone
marrow, and multiplying the mass of the 2 femora by 6.5
to obtain the total TfR mass in the bone marrow. The
total body mass of cellular TfR (total TfR mass) was then
calculated as the sum of the total masses of TfR in liv-
er, spleen, marrow, and RBC. The mass of RBC TfR was
converted into number of TfR molecules per reticulocyte,
using the following formula:
Total mass of RBC TfR (µg)×10-6×6.023×1023
N TfR/retic. = 
190,000 × N retic. (/µL)×70µL/g×BW (g)
where 6.023×1023 is Avogrado’s number, 190,000 the
molecular weight of TfR, and 70 µL/g the blood volume
relative to body weight (BW).
Statistical methods
All results are presented as mean ± standard devia-
tion (M ± SD) and expressed either in absolute values or
as percentages of a baseline value. Comparisons of base-
line values with later measurements in the same group
of animals were carried out by paired Student's t tests.
Comparisons between groups were carried out with Stu-
dent's t-tests, with Welsch's correction in case of
unequal variances. R correlation coefficients between
two variables were computed in least squares regression
equations. Most statistical analyses were carried out
with Excel 97 (Microsoft Corporation, Redmond, Wash-
ington, USA) or Prism 2.0 (GraphPad Software Inc., San
Diego, California, USA) software.
Results
The number of TfR molecules per reticulocyte was
measured in normal rats as well as in animals experi-
encing hemolysis, phlebotomies, hypertransfusions, thi-
amphenicol treatment or acute inflammation (Table 1).
Normal rats had an average of 54,000 TfR molecules per
reticulocyte and this did not vary significantly from the
values found in most other groups of animals. However,
after one week of phlebotomies, functional iron defi-
ciency resulted in TfR numbers more than double normal
values. Less severe degrees of functional iron deficiency
did not result in such increased reticulocyte TfR numbers.
TfR numbers were also increased on day 1 after injection
of turpentine oil but normalized on day 2. Finally, in the
early phase of erythroid regeneration after acute hemolysis,
TfR expression was increased in reticulocytes. This was
even more prominent in the recovery phase immediate-
ly after thiamphenicol-induced red cell aplasia. 
The number of TfR molecules per reticulocyte was also
investigated in relationship to age, iron status and rHu-Epo
Table 1. Number of TfR molecules per reticulocyte in rats in
various conditions not receiving iron or rHuEpo.
Condition Day N Tf Retic Retic TfR (x 103
saturation (%) (x103/µL) molecules
/retic)
Normal 0 9 29±14 11.7±3.6 849.3±245.2 54.0±23.2
Hemolysis (PNH x 1) 2 4 31±10 13.9±2.8 839.0±133.4 72.0±11.6
5 4 25±8 29.5±2.9# 1615.2±207.7# 120.5±23.9#
10 4 28±8 40.7±8.4° 2719.9±614.3° 76.9±14.6
16 8 25±8 8.4±1.3° 623.0±116.0* 36.0±11.9
Hemolysis (PNH x 3) 14 2 5±2° 42.5±2.6# 2355.1±115.2# 44.4±9.2
18 2 6±0° 16.8±2.4 1203.0±313.2 63.5±1.6
Phlebotomy 5 5 5±2# 42.5±10.5° 1576.4±382.4# 68.2±6.4
9 4 1±1# 34.6±1.9# 1651.6±74.3# 139.9±21.8#
14 8 3±1# 41.6±6.0# 2024.6±315.4# 121.2±24.1#
Hypertransfusion 5 4 49±13* 2.5±0.8# 239.5±76.4# 35.5±13.2
(normal blood) 8 5 59±9° 1.0±0.3# 105.2±29.6# 52.5±22.6
Hypertransfusion 5 4 82±9# 3.9±0.8# 327.8±65.9# 72.7±23.7
(retic-rich blood) 11 4 83±11# 9.6±0.8 720.4±104.7 72.9±42.8
Hypertransfusion 5 4 54±11° 0.7±0.1# 82.7±18.5# 41.6±7.1
(retic-poor blood) 8 4 67±12# 1.0±0.4# 112.3±41.1# 54.9±29.2
11 4 87±12# 1.0±0.5# 123.7±53.3# 69.6±20.4
16 4 87±10# 0.8±0.3# 87.8±24.8# 33.7±12.5
Thiamphenicol (4 days) 4 4 44±5* 2.8±1.1# 203.1±85.8# 43.4±11.5
7 3 8±3° 8.2±3.1 1215.4±245.1* 240.4±46.2#
11 3 6±1° 13.1±1.3 807.7±98.9 68.3±16.7
Thiamphenicol (9 days) 10 3 — 1.5±0.0# 82.9±3.1# 54.4±11.7
Inflammation 1 4 9±2* 6.7±0.5° 449.9±25.6° 90.4±18.5*
2 4 20±3 7.8±1.5 560.4±95.2* 70.3±24.6
4 4 18±6 8.3±2.6 658.1±199.2 62.7±30.0
PNH = phenylhydrazine. p values: *< 0.05, °<0.01, #<0.001 for comparison with
normal animals. Retic = reticulocytes.
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treatment (Table 2). Older rats expressed more TfR in retic-
ulocytes than younger animals. Iron supplementation for
2 weeks or iron overload for 3 months did not result in
modifications of reticulocyte TfR numbers. Whereas low
doses of rHuEpo (10 U/day) did not alter reticulocyte TfR
expression, higher doses (50 to 150 U/day) resulted in sig-
nificantly higher numbers of TfR but there was no differ-
ence between these latter two dose levels. 
There was a strong correlation (r=0.60, p <0.001)
between the fraction of injected radioactivity taken up by
reticulocytes and their relative contribution to the total
mass of TfR. However, in situations of intense stimulation
of erythropoietic activity, reticulocyte radioiron uptake
became much in excess of their relative TfR mass. For
instance, whereas in normal rats 31±7% of the radioac-
tivity went to reticulocytes (35±8% of total TfR mass)
and 53±3% to the bone marrow (57±8% of total TfR
mass), day 9 phlebotomized animals had 68±3% of
radioactivity in reticulocytes (49±8% of total TfR mass)
and 16±8% in the bone marrow (34±8% of total TfR
mass).
Hypertransfusion with normal (Figure 1), reticulocyte-
poor (Figure 2) or reticulocyte-rich (Figure 3) blood
resulted in polycythemia-induced red cell aplasia. The
total mass of marrow and spleen TfR was decreased
(Table 3), demonstrating a severe reduction in the num-
ber of erythroblasts. Animals receiving normal or retic-
ulocyte-poor blood had very low reticulocyte counts.
Maximal suppression of erythropoietic activity was
already achieved by day 5 but sTfR levels continued to
decrease slowly and stabilized only later around 50% of
baseline values when normal blood was transfused and
30% of baseline values when reticulocyte-poor blood
was used. In rats transfused with reticulocyte-rich blood,
reticulocyte counts first increased on day 1 before
decreasing to levels that remained significantly higher
than in the other groups. In contrast to the other ani-
mals, sTfR levels did not decrease but followed the evo-
lution of reticulocyte counts. Despite adequate suppres-
sion of erythropoietic activity as documented by dimin-
ished ETU and a reduced mass of TfR in marrow and
spleen (Table 3), sTfR levels remained consistently above
baseline values (Figure 3). Indeed, whereas endogenous
reticulocyte counts were probably considerably
decreased, transfused reticulocytes maintained a nor-
mal total mass of reticulocyte TfR (Table 3). These donor
Table 2. Number of TfR molecules per reticulocyte in normal, iron supplemented or iron overloaded rats of young or old age
treated with rHuEpo.
Age group Iron status rHuEpo dose Day N Tf saturation (%) Retic (%) Retic (x103/µL) TfR (x103 molecules
(U/d) /retic)
Young Normal 0 0 6 18±2 6.4±2.8 543.7±199.8 67.1±17.0
0 4 4 22±5 7.0±0.6 537.7±69.1 54.2±11.1
0 8 4 16±5 10.0±2.4 777.5±152.7 54.2±29.4
0 12 4 12±7 10.0±3.9 866.0±280.3 55.5±13.5
Young Normal 10 4 4 15±1 11.3±4.2 906.2±299.4 55.2±17.4
10 12 4 13±7 10.2±3.0 767.0±241.0 58.8±35.4
Young Normal 50 4 4 6±3# 17.9±2.3# 1485.2±168.9# 103.1±52.3
50 8 4 3±2# 12.8±0.9° 1159.2±67.4# 130.4±29.5*
50 12 4 5±2# 16.9±3.9° 1626.7±333.0° 114.1±61.0
Young Normal 150 4 4 2±1# 16.7±3.6° 1440.2±284.1° 115.3±17.9°
150 8 4 3±0# 17.8±2.6# 1697.5±257.6# 141.1±32.8*
150 12 4 1±1# 15.4±1.7# 1704.0±198.0# 163.8±53.5*
Young Supplemented 0 0 6 26±2# 8.1±1.9 669.5±221.3 61.2±24.6
0 12 4 21±1* 8.0±1.1 674.2±98.8 63.7±13.2
50 12 4 17±6 17.9±0.4# 1783.7±57.3# 148.1±51.8*
150 12 4 6±2# 19.1±1.9# 2037.5±236.0# 126.7±29.0*
Old Normal 0 0 4 22±4 3.6±0.6 315.5±80.5 113.9±35.4
0 16 4 20±6 3.0±0.5 281.7±40.6 105.6±32.0
Old Overloaded 0 0 4 26±4 6.6±1.4* 570.7±116.3* 100.3±9.4
10 16 4 20±3 7.6±0.7# 719.0±79.0# 113.5±25.1
50 16 4 14±3* 10.1±1.2# 1047.7±125.1# 261.7±54.1°
150 16 4 12±2* 12.5±1.8# 1357.7±220.2# 268.5±82.2*
p values: *< 0.05; °<0.01; #<0.001 (young rats are compared with young normal animals receiving no rHuEpo, old rats with old normal rats receiving no rHuEpo). Retic =
reticulocytes.
Table 3. ETU and total mass of TfR in reticulocytes, marrow
and spleen in rats transfused with normal, reticulocyte-poor
and reticulocyte-rich blood and sacrificed on day 8.
Normal rats Rats hypertransfused with:
Normal blood Retic-poor blood Retic-rich blood
N=9 N=5 N=4 N=4
Hct (%) 45.7±1.9 63.4±5.7° 66.3±2.2# 64.7±4.0#
Retic TfR (µg) 207±87 25±10# 30±13# 244±115
Marrow TfR (µg) 316±63 46±20# 60±9# 84±30#
Spleen TfR (µg) 17±16 2±1# 3±2# 9±9*
ETU  (µMol/L/d) 88±33 16±6# 22±7# 40±6°
p values: *< 0.05, ° <0.01, #<0.001 for comparison with normal animals. Retic
= reticulocytes.
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reticulocyte-associated TfR remained functional and
took up adequate amounts of radioiron. Therefore, there
was an excellent correlation between the total mass of
erythron TfR and the ETU in the various groups of nor-
mal and hypertransfused animals (r=0.97, p =0.035).
Discussion
Although virtually all cells except mature red cells
have TfR on their surface, the largest numbers are on the
erythron. Previous estimates of erythroid cell TfR num-
bers were based on in vitro binding experiments of
radioiodinated transferrin to erythroid cells. Many more
receptors are seen on CFU-E than on BFU-E.4-6 Assum-
ing a unimolecular interaction between transferrin and
TfR molecules in fetal liver erythroid cells, TfR numbers
were evaluated to be about 300,000 on early nor-
moblasts and up to 800,000 on intermediate nor-
moblasts before declining to about 100,000 on reticu-
locytes.7 TfR are lost during reticulocyte maturation so
that TfR numbers vary with reticulocyte age and none
is detected on mature red cells.8,29,30 Using direct mea-
surements we found TfR numbers in reticulocytes to be
about half those previously reported. Similar31 as well as
lower32 or higher33 numbers of rat reticulocyte TfR have
been reported by others. In another study on human
reticulocytes, very low numbers of TfR (53±40 per cell)
were found.34 Others have demonstrated that there are
fewer binding sites than immunoreactive TfR mole-
cules.29 However, some authors have emphasized the
difficulty in estimating TfR numbers per reticulocyte in
binding experiments since binding studies may vary
according to the amount of transferrin present or the
rate of intracellular internalization.29,35 In addition, there
is some controversy in the literature concerning binding
relationships between TfR and transferrin, some assum-
ing a 1:1 and others a 1:2 relationship.1-3, 33 If a 1:2 rela-
tionship is assumed, then previous estimates7 should be
halved and so become much closer to our figures. Final-
ly, TfR numbers vary considerably with the age of the
animals and this might account for some discrepancies
Figure 1. Evolution of the hematocrit, reticulocytes and sTfR
levels in rats hypertransfused with normal blood. 
Figure 2. Evolution of the hematocrit, reticulocytes and sTfR
levels in rats hypertransfused with reticulocyte-poor blood. 
Reticulocyte transferrin receptor 249
haematologica vol. 86(3):March 2001
among studies. TfR expression was surprisingly higher in
older animals, but as the number of reticulocytes was
about half that in younger rats, the total mass of retic-
ulocyte TfR was very similar. Although no such effect has
been observed in human except in infants,36,37 serum
sTfR concentrations in rats have been reported to be
lower in older animals.14 However, the total mass of
serum sTfR remains stable with age because the blood
volume also increases with age.
TfR numbers were altered in a number of situations.
Iron overload did not modify TfR expression in reticulo-
cytes but this is not surprising because iron loading
occurs mostly in non-erythroid cells. On the other hand,
contrarily to previous reports,32 iron deficiency expect-
edly induced higher TfR numbers but lower degrees of
functional iron deficiency did not. The transient increase
in TfR expression 24 hours after an episode of acute
inflammation is more difficult to interpret. However, the
total mass of reticulocyte TfR did not change signifi-
cantly because the number of reticulocytes decreased.
It has been previously reported that serum sTfR decreas-
es transiently after acute inflammation.14 This consistent
early decrease of serum sTfR values without significant
change in the mass of tissue TfR suggests that acute
inflammation could accelerate the clearance of sTfR
from the serum. However, it is also possible that lower
serum sTfR values are only the result of an expansion of
plasma volume mediated by cytokines such as inter-
leukin-6.38,39 Treatment with high doses of rHuEpo
resulted in 2.5-fold higher numbers of TfR and this was
relatively independent of functional iron deficiency
because the increment was similar in normal, iron-sup-
plemented and iron-overloaded animals that had very
different transferrin saturations (Table 2). This is in vivo
confirmation of the in vitro observation that Epo direct-
ly increases TfR expression in erythroid cells.1,11 Finally,
TfR expression was considerably increased in the early
recovery phase after acute hemolysis or thiamphenicol-
induced red cell aplasia but this occurred only tran-
siently as the number of TfR per cell rapidly normalized
despite ongoing reticulocytosis. Such an increase has
been observed by others32 and is consistent with younger
reticulocytes shifting from the bone marrow to the cir-
culation before a more mature population of cells fol-
lows suite. All these observations provide evidence that
factors that have been shown to determine reticulocyte
TfR expression in culture are also operational in vivo.
In situations of intense erythropoietic activity, radio-
iron uptake occurred preferentially in the large number
of reticulocytes to the disadvantage of spleen or mar-
row erythroblasts, although they expressed comparable
total numbers of TfR. It thus appears that, when iron is
scarce relative to the demand for it, circulating reticu-
locytes more readily have access to transferrin iron and
thus reinforce iron restriction in marrow or spleen ery-
throblasts. However, this aggravation of functional iron
deficiency only occurs in the presence of massive retic-
ulocytosis, a finding rarely encountered in humans. 
In vitro incubation of reticulocytes20,21 or erythro-
blasts22 as well as various tumor cell lines19,20,40 was fol-
lowed by the release of TfR into the medium. Release of
soluble TfR by erythroblasts occurred in the middle to
late phase of maturation, the period of maximal mRNA
and protein expression.22 Exosomes containing intact
TfR as well as truncated sTfR have been shown to be
released by reticulocytes. Segregation of TfR and other
obsolete proteins to a class of endosomes where fusion
and budding occurs, results in the formation of multi-
vesicular bodies that can fuse with plasma membrane
and release exosomes into the circulation.41-43 Howev-
er, it has been shown that less than 1% of human serum
TfR is intact receptor consistent with an exosomal ori-
gin, whereas virtually all is in the form of a soluble trun-
cated extracellular domain.44 Thus proteolysis occurs
mostly at the surface of exosomes within the multi-
vesicular body prior to exocytosis.45 Re-incubation of
externalized human exosomes failed to generate a sol-
uble form of TfR.45 However, other studies with rat retic-
ulocytes have suggested that the production of sTfR was
Figure 3. Evolution of the hematocrit, reticulocytes and sTfR
levels in rats hypertransfused with reticulocyte-rich blood. 
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still possible from externalized exosomes.21
In vivo, an excellent correlation between cellular TfR
and soluble TfR has been demonstrated by ferrokinetic
studies.14,15 However, the cell population predominant-
ly involved in TfR shedding has not been clearly identi-
fied. Based on a number of 5.3×109/kg normoblasts46
and knowing that the vast majority of them are inter-
mediate normoblasts expressing 800,000 TfR, the nor-
moblast TfR mass can be estimated at 4.24×1015/kg. This
is almost four times more than the reticulocyte TfR cell
mass of 1.13x1015/kg, based on a number of 8.2×109/kg
marrow reticulocytes plus 3.1×109/kg blood reticulo-
cytes46 expressing 100,000 TfR. Therefore, the erythrob-
last compartment, not reticulocytes, should be the main
source of sTfR. Indeed, serum sTfR levels parallel TfR
expression on erythroblasts47 and the highest reported
levels were observed in thalassemic patients who are
characterized by ineffective erythropoiesis with consid-
erably expanded marrow erythropoiesis but low reticu-
locyte counts.15 However, we show here that circulating
reticulocytes can contribute considerably to serum sTfR
levels , and this finding is in keeping with recent obser-
vations in athletes.48 Despite severe erythroid aplasia
induced by hypertransfusion, serum sTfR levels remained
normal in rats repeatedly receiving reticulocyte-rich
blood. This contrasted with the situation in rats trans-
fused with normal or reticulocyte-poor blood in which
sTfR values declined progressively to reach levels pro-
portional to the number of circulating reticulocytes.
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Potential implications for clinical practice
Soluble tranferrin receptor levels are influenced not
only by the mass of erythroblasts but also depend on
transferrin receptor expression on reticulocytes.
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